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Abstract
Background: Diabetic maculopathy, the leading cause of vision loss in patients with type 2 diabetes, is characterized by
hyper-permeability of retinal blood vessels with subsequent formation of macular edema and hard exudates. The degree of
hyperglycemia and duration of diabetes have been suggested to be good predictors of retinal complications. Intervention
studies have determined that while intensive treatment of diabetes reduced the development of proliferative diabetic
retinopathy it was associated with a two to three-fold increased risk of severe hypoglycemia. Thus we hypothesized the
need to identify downstream glycemic targets, which induce retinal vascular permeability that could be targeted
therapeutically without the additional risks associated with intensive treatment of the hyperglycemia. Betacellulin is a 32 kD
member of the epidermal growth factor family with mitogenic properties for the retinal pigment epithelial cells. This led us
to hypothesize a role for betacellulin in the retinal vascular complications associated with diabetes.
Methods and Findings: In this study, using a mouse model of diabetes, we demonstrate that diabetic mice have
accentuated retinal vascular permeability with a concomitant increased expression of a cleaved soluble form of betacellulin
(s-Btc) in the retina. Intravitreal injection of soluble betacellulin induced retinal vascular permeability in normoglycemic and
hyperglycemic mice. Western blot analysis of retinas from patients with diabetic retinopathy showed an increase in the
active soluble form of betacellulin. In addition, an increase in the levels of A disintegrin and metalloproteinase (ADAM)-10
which plays a role in the cleavage of betacellulin was seen in the retinas of diabetic mice and humans.
Conclusions: These results suggest that excessive amounts of betacellulin in the retina may contribute to the pathogenesis
of diabetic macular edema.
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Introduction
The incidence of diabetes world-wide, is expected to reach
epidemic proportions by 2025. Progression of diabetic retinopathy
often results in diabetic macular edema, which is a consequence of
the breakdown of the blood-retinal barrier, increased retinal
vascular permeability and leakage of plasma from small blood
vessels in the macula leading to loss of central vision. While
epidemiological studies have suggested that glycemic control plays
a major role in the development of vascular complications of
diabetes[1], current insulin therapies for control of glucose
metabolism have not been successful in the prevention of long-
term complications[2,3]. Intervention studies have determined
that while intensive treatment of diabetes reduced the develop-
ment of proliferative diabetic retinopathy [4], it was associated
with a two to three-fold increased risk of severe hypoglycemia[5]
as well as an increased risk of mortality from cardiovascular
disease [6]. Laser photocoagulation as well as anti-VEGF therapies
have shown significant promise in the treatment of proliferating
vessels in proliferative diabetic retinopathy. However, DME
appears to be more resistant to these treatment approaches,
suggesting that other factors might contribute to this phenotype.
These observations led us to hypothesize the presence of a novel
factor that contributes to the increased retinal vascular perme-
ability and/or retinopathy seen in diabetes.
Betacellulin (BTC) is a 32 kD member of the epidermal growth
factor (EGF) family that was originally isolated from the
conditioned medium of a mouse pancreatic b-cell tumor line[7].
BTC is a glycosylated (N- and O-linked) protein with an apparent
molecular weight of 32 kDa, generated by cleavage of a 178-
amino acid membrane anchored precursor protein pro-BTC.
BTC binds and activates the EGF receptor (EGFR/erbB-1) and
erbB-4[8,9,10]. BTC has been shown to be expressed in the
human pancreas by pancreatic b cells [11,12,13] as well in other
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into insulin secreting cells[13,14,15]and induce pancreatic b-cell
neogenesis in diabetic mice[16]. Because of the proliferative effects
of BTC on retinal pigment epithelial cells we hypothesized that it
may contribute to increased retinal vascular permeability and the
pathogenesis of diabetic macular edema. We have compelling
evidence that betacellulin can increase retinal vascular permeabil-




Recombinant human VEGF was a kind gift from Genentech,
CA and recombinant betacellulin was purchased from R&D.
Antibodies: polyclonal anti-mouse and anti-human betacellulin
antibody (R&D), monoclonal anti-ADAM-10 (Calbiochem) and
HRP-conjugated anti-rabbit, anti-mouse IgG antibodies (Amer-
sham Pharmacia Biotech) and anti-goat IgG (Santa Cruz). Post
mortem human eyes were obtained from he National Disease
Research Interchange (NDRI), Philadelphia. Postmortem time
ranged from 3–10 hours.
Immunoblotting
Lysates from mouse or human retina prepared using sonication
on ice with RIPA buffer (Boston Bioproducts) containing EDTA
free protease inhibitors (Roche) were subjected to SDS-PAGE.
Proteins were probed with antibody and detected with either a
HRP-conjugated anti-rabbit or anti mouse IgG antibody (Amer-
sham Pharmacia Biotech, Piscataway, NJ) followed by ECL. The
blots were restripped with Restore
TM solution (Thermo Scientific)
for 30 minutes and reprobed as indicated.
Animals
6–8 week old C57BL6 mice (Jackson Laboratories, Maine) were
used in this study. The animals were cared for in accordance with
the ARVO statement for the Use of Animals in Ophthalmic and
Vision research. All experimental procedures used aseptic sterile
techniques and were approved by the Animal Care and Use
Committee of the Cleveland Clinic (ARC08792).
Experimental Diabetes
6–8 week old mice were rendered diabetic with 3 consecutive
daily intraperitoneal injections of STZ (55 mg/Kg) freshly
dissolved in citrate buffer (pH 4.5). Control mice were given
injections of buffer alone. Development of diabetes (defined by
blood glucose greater than 250 mg/dl) was confirmed 1 week after
the initial injection (One TouchHltraHTest Strips and One
TouchHUltraMini
TMglucometer).
Blood retinal barrier quantitation
Vascular permeability in the retina was quantitated after 3–4
weeks of diabetes using an Evans blue quantitation technique as
described previously [17]. Briefly 3–4 weeks after the onset of
diabetes or 24 hours after intravitreal injections, mice were
anesthetized with isofluorane and injected intravenously (via the
tail vein) with 200 ml of Evans Blue dye (Sigma) at a concentration
of 45 mg/Kg. Quantitation of the retinal barrier breakdown was
assessed as described previously [18]. Additionally, retinas from
Evans Blue injected mice were examined by fluorescence
microscopy (Nikon). For quantitative analysis of vascular leakage,
retinal images were batch processed using a customized macro
generated in Image-Pro Plus 6.1 (Media Cybernetics, Silver
Spring, MD). In each image, leakage areas were segmented using a
gray-level threshold set between 230–255. Intensely stained vessels
protruding from binarized leakage areas were removed using
successive passes of morphological erosion and dilation filters;
areas of processed, segmented regions were then exported to
Excel. In original, unprocessed images, a threshold value obtained
from an automated search for histogram minima was used to
segment the entire retina from background for percent leakage
calculations (leakage area divided by total retinal tissue area).
Finally, boundaries of binarized leakage regions were extracted
using a Sobel filter, pseudo-colored, and then superimposed upon
original images to allow visualization of segmented vascular
leakage regions.
Results
Increased soluble betacellulin in the retinas of diabetic
mice with hyper-permeable retinal vessels
Steptozotocin-induced diabetic mice with hyperglycemia (fast-
ing blood sugar $200 mg/ml) were examined for increases in
retinal vascular permeability using an Evans Blue leakage assay. As
described previously [17], we observed a modest increase in dye
leakage from the retinal vessels of diabetic mice (Fig. 1b,c) when
compared with control normoglycemic mice (Fig. 1a,c). We
examined the expression of betacellulin in the pancreas and retinas
of control and diabetic mice. It was interesting to note that in the
pancreas the majority of betacellulin was present as the cleaved
soluble form (s-BTC) compared with the abundance of the higher
molecular weight membrane bound pro-form (Pro-BTC) in
normal mouse retinas (Fig. 1e). There appeared to be a trend
towards a slight increase in the pro-BTC in the pancreas of
diabetic mice (Fig. 1d). In the mouse retina the cleaved low-
molecular weight form of active soluble betacellulin (s-BTC) was
significantly increased in hyperglycemic mice (Fig. 1e,f) when
examined by western blot analysis.
Increase in retinal soluble betacellulin causes increased
retinal vascular permeability in diabetic mice
To determine if the increase in soluble active betacellulin seen in
diabetic mice could contribute to increased vascular permeability
we examined whether increased concentration of betacellulin in
the retina could induce retinal vascular leakage in normal mice.
Intravitreal injections of increasing doses of recombinant soluble
betacellulin (0–300 ng) resulted in increased retinal hemorrhage
(Fig. 2a upper panel,arrowheads) and increased retinal vascular
permeability (Fig. 2b lower panel) in a dose dependent manner,
similar to that induced by vascular endothelial growth factor
(VEGF).
Combination of hyperglycemia and increased
intravitreous betacellulin causes accentuated retinal
vascular leakage
Since all patients with diabetes do not develop macular edema,
we postulated that a combination of hyperglycemia and increased
intravitreous betacellulin might lead to a more severe phenotype.
Injection of 200 ng of recombinant betacellulin intravitreally in
hyperglycemic mice induced a marked accentuation of retinal
vascular leakage as detected by extravasation of intravascular
Evans Blue dye (Figs. 2f,g) when compared with leakage induced
in normoglycemic mice (Figs. 2d,g).
Since VEGF has been proposed to be a critical factor in the
increase in retinal vascular permeability in proliferative diabetic
retinopathy (PDR) and diabetic macular edema (DME), we
wanted to determine if the effect of betacellulin was VEGF-
Betacellulin and Diabetes
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injected with betacellulin (Fig. S1) indicating that betacellulin
increased retinal vascular permeability via a VEGF-independent
pathway.
Increased expression of soluble betacellulin in human
diabetic retinas
Betacellulin is expressed as a membrane anchored precursor
protein (pro-betacellulin) containing an extracellular N-terminal
ectodomain, a transmembrane domain and a cytoplasmic
domain[13,19]. Like other members of the EGF family, the
ectodomain of betacellulin can be proteolytically cleaved to release
a soluble form of the protein. Protein levels of the pro-betacellulin
as well as its cleaved soluble form were examined by western blot
analysis in post-mortem retina tissue from healthy donors, patients
with diabetes with no clinical diagnoses of retinopathy and patients
with diabetic retinopathy. Diabetic retinas showed evidence of
increased pro-BTC (38 kD) as well as the cleaved s-BTC (19 kD)
compared with retinas from controls (Fig. 3a). Both the membrane
anchored and soluble forms of betacellulin are believed to be
biologically active, binding to ErbB receptors. The ratio of s-BTC
to pro-BTC was significantly increased in the retinas of patients
with diabetes (Fig. 3c).
Increased expression of ADAM10 in diabetic mouse and
human retinas
Recent studies have determined that ADAM-10 (a disintegrin
and metalloproteinase-10) can mediate the constitutive and
activated shedding of pro-betacellulin[20,21]. In order to deter-
mine if ADAM-10 plays a role in the increased expression of the
soluble form of betacellulin in the retinas of diabetic mice we
performed western blot analyses using an ADAM-10 antibody. We
found that ADAM-10 (62 kD mature form) was increased in the
retinas of streptozotocin-induced hyperglycemic mice (Fig. 4a) but
not in mice injected intravitreally with recombinant VEGF
(Fig. 4b). Immunoblot analysis on retinas from diabetic patients
with without a clinical diagnosis of retinopathy determined an
increase in mature ADAM 10 when compared with retinas from
healthy controls (Fig. 4c,d). While the exact mechanism by which
ADAM-10 is increased in the retinas of diabetics remains to be
determined, these results indicate that ADAM-10 may contribute
to the cleavage of membrane bound betacellulin that causes
Figure 1. Diabetic mice show augmented retinal vascular permeability and increased expression of cleaved betacellulin in the
retina. Leakage of Evans Blue dye from mouse retinal vessels in representative a) normoglycemic and b) hyperglycemic mice was quantitated in
whole mount retinas one hr after perfusion with the dye(n=8). (c). Representative Western blot analysis of betacellulin in pancreas (d) and retinas (e)
from control and streptozotocin-induced diabetic mice. (f) densitometric quantitation of the ratio of sBTC to ProBTC in mouse retina from control
(n=12) and diabetic (n=12) mouse eyes. ***p=0.008 (ANOVA).
doi:10.1371/journal.pone.0013444.g001
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the disease.
Discussion
Diabetes mellitus is a global disease with considerable morbidity
and mortality. The total number of people with diabetes is
expected to reach 300 million by the year 2025, with the majority
of increased cases predicted to be in developing countries. The
disease is classified into type I diabetes (previously referred to as
‘‘insulin dependent’’ or ‘‘juvenile onset’’), characterized by an
absolute insulin deficiency as a consequence of destruction of the
insulin secretory pancreatic b cells of the islets of Langerhans; and
type II diabetes (‘‘non-insulin dependent’’ adult-onset’’ which is
characterized by an insulin secretory defect of the b-cell and
insulin resistance in peripheral tissues. Diabetic retinopathy is a
common complication of both type I (50% incidence) and type II
(30% incidence)[22,23,24,25,26] diabetes. Diabetic retinopathy
can be broadly divided into two clinical stages: non-proliferative
and proliferative diabetic retinopathy (PDR). In non-proliferative
diabetic retinopathy, the earliest visible sign is the formation of
microaneurysms. Increased capillary permeability, results in the
leaking of fluid into the surrounding retinal tissue, pooling around
the macula causing macular edema and loss of visual acuity. It is
believed that the retinal neovascularization in PDR results from
ischemia and the consequent release of local hypoxic and pro-
angiogenic factors such as VEGF[27], hypoxia-inducible fac-
tors[28] and erythropoietin[29]. These factors may stimulate
abnormal vessel growth extending into the vitreous of the eye,
leading to hemorrhage and visual loss. Laser photocoagulation as
well as anti-VEGF therapies have shown significant promise in the
treatment of proliferating vessels in PDR. While PDR appears to
be extremely responsive to treatment with VEGF inhibitors, early
studies indicate that the response to these drugs in retinal edema is
often partial and requires higher doses[30]. However, DME
appears to be more resistant to these treatment approaches,
suggesting that other factors might contribute to the retinal
vascular leakage. These results and other recent studies have
Figure 2. Intravitreal injection of betacellulin induces increased retinal haemorrhage and augmented retinal vascular permeability
in normal and diabetic retinas. Dose response of the effect of intravitreal injection of betacellulin (50–300 ng), VEGF (200 ng) and PBS in
normoglycemic mice on a) retinal haemorrhage as seen in a bright field image of dissected posterior pole of mouse eyes. Arrowheads indicate areas
of hemorrhage. For BTC-300, inset is magnification of boxed area b) Evans Blue dye leakage in flat mounted retinas. Leakage of Evans blue dye from
retinal vessels of normoglycemic (c,d) and hyperglycemic (e,f) mice injected intravitreally with PBS(c,e) or 200 ng recombinant mouse betacellulin
(d,f). Results are quantitated (g). * p,0.009.
doi:10.1371/journal.pone.0013444.g002
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anhydrase[31,32] and erythropoietin[33,34], play a role in
diabetic retinal edema. Our results suggest that cleaved betacellu-
lin contributes to increased retinal vascular leakage in diabetes.
ADAMs and ADAM-10 in particular have been recently
reported to be novel regulators of vascular permeability[7,35,36]
and our data indicates that this might occur via increased
expression of betacellulin. Cleavage of the membrane-anchored
forms of BTC to release a secreted form occurs principally by
ADAM-10 (a disintegrin and metalloprotease-10)[20,21,37,38] as
well as endothelin-1[39]. ADAM-10 has recently been shown to
induce endothelial cell permeability via regulation of VE-
cadherin-dependent endothelial cell functions[36]. Whether cleav-
age of betacellulin is necessary for the increased vascular
permeability by ADAM-10 occurs in the retina or elsewhere
remains to be determined.
We have examined betacellulin levels in the plasma and found
no significant increase in betacellulin in the circulating plasma of
patients with PDR (n=23) (Fig. S2). While this suggests that the
betacellulin might be synthesized or processed in the retina we
cannot exclude the possibility that the ELISA used to measure
betacellulin may lack the sensitivity to detect small changes in
circulating levels.
Recent studies have suggested Neurod-Btc gene therapy to be a
promising approach to induce islet regeneration for the treatment
of insulin-dependent diabetes[40]. Our data suggest that we
should proceed with caution in this regard as there is a likelihood
of inducing or worsening the ocular complications of macular
edema. We observed that the magnitude of the effect of
intravitreal betacellulin on retinal vascular permeability was
equivalent to that of VEGF. While much attention has been
focused on the role of VEGF in the pathophysiology of PDR and
DME, it is becoming increasingly evident that other vasoperme-
ability factors are involved [32,41] and more attention should be
focused on targeting these factors as therapeutics. Recent findings
have also suggested the need to re-evaluate the current diagnostic
criteria for diabetes, and the risk of complications based on fasting
plasma glucose levels, as neither macrovascular nor microvascular
complications seem to respect a strict glycemic threshold [3].
Perhaps glycemia in combination with additional vasopermeability
factors might be a more reliable prognostic indicator. In summary,
our data suggests that betacellulin plays an important role in the
development of increased retinal vascular permeability in diabetes
and inhibitors of ADAM-10 or betacellulin signaling might be
clinically useful in preventing the development and progression of
macular edema in this disease.
Figure 3. Increased expression of betacellulin in retinas of humans with diabetes. Western blot analysis of (a) BTC (b) GAPDH in retina
tissue from human donors with no diabetes, diabetes or diabetes with diabetic retinopathy. (c) Densitometric quantitation of the ration of sBTC to full
length BTC using GAPDH as a reference. ** p=0.01 * p=0.03.
doi:10.1371/journal.pone.0013444.g003
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Figure S1 Betacellulin induces retinal vascular leakage indepen-
dent of VEGF. Retinas from mice injected intravitreally with PBS
or betacellulin (200 ng) or no injection (control) were evaluated for
VEGF protein 24 hours post injection.
Found at: doi:10.1371/journal.pone.0013444.s001 (0.74 MB
TIF)
Figure S2 No significant increase in circulating plasma beta-
cellulin in patients with proliferative diabetic retinopathy. Plasma
was prepared from whole blood from patients with no diabetes,
Figure 4. Increased expression of ADAM-10 in diabetic retinas. Western blot analysis of ADAM-10 in retina tissue from (a) control and STZ
induced diabetic mice (b) control and intravitreal VEGF injected mice and (c) human retinas from patients with no diabetes, diabetes or diabetes with
diabetic retinopathy(d) Densitometric quantitation of mature ADAM-10 (mADAM-10) relative to actin on the same blot. ** p#0.03.
doi:10.1371/journal.pone.0013444.g004
Betacellulin and Diabetes
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13444diabetes with no evidence of retinopathy and proliferative diabetic
retinopathy and analyzed by ELISA for betacellulin.
Found at: doi:10.1371/journal.pone.0013444.s002 (0.54 MB
TIF)
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